Peripheral blood lymphocytes (PBL) were obtained from HIV-1-infected patients at different stages of disease. The absolute number of IgM-, IgG-, and IgA-producing lymphocytes per 106 PBL was increased 2.8-, 3.4-, and 1.9-fold, respectively, compared with normal controls. 2-17% of IgG-secreting patient cells reacted with the gpl60 envelope glycoprotein of HIV-1 (a 737-fold increase over background), while 1-9% reacted with p24 (140-fold over background). In addition to this HIV-specific B cell activation, the number of lymphocytes reactive with nonviral antigens such as DNA, myosin, actin, trinitrophenylated keyhole limpet hemocyanin, and ovalbumin was increased by a mean of 17.9-fold. Evidence suggests that the latter changes reflect an HIV-induced polyclonal B cell activation unrelated to the production of anti-HIV antibodies. For example, the proportion of IgG anti-gpl6O-and anti-p24-secreting lymphocytes declined in patients with advanced disease, whereas the number of B cells producing antibodies to non-HIV antigens rose. Moreover, CD4 cell count and T4/T8 ratio showed a significant inverse correlation with the degree of polyclonal activation but not with anti-HIV responsiveness. These observations demonstrate that both quantitative and qualitative changes in B cell activation accompany (and may be predictive of) disease progression in HIV-infected individuals. (J. Clin.
Introduction
Infection with HIV-1 induces profound abnormalities in the host's immune system, including a loss of CD4 T cells (1) (2) (3) (4) (5) , suppression of responses to T-dependent antigens (6) (7) (8) (9) , and abnormal activation of B lymphocytes (9, 10) . In the first year after infection, many patients develop hypergammaglobulinemia (11) (12) (13) , characterized by increased levels of serum antibodies reactive with self antigens (such as T cells and nuclear determinants; foreign antigens such as trinitrophenyl (TNP)l and sheep red blood cells; and HIV viral proteins, including gp160 and p24 [14] [15] [16] [17] [18] [19] [20] [21] [22] ).
This B cell activation was initially believed to be "polyclonal" in nature since: (a) it included antibodies reactive with a large number of different antigens (9) ; (b) components of the HIV virus (especially gp4 1) were reported to induce normal B cells to polyclonally proliferate and secrete Ig in vitro (23) (24) (25) (26) ; and (c) the number of Ig-secreting lymphocytes increased in HIV-infected patients, whereas the total number and proportion of peripheral blood B cells did not (3, 9, 27, 28) . Yet more recent studies find little evidence of polyclonal memory B cell activation in HIV+ patients (29, 30) and the stimulatory effects of gp41 are now regarded primarily as a reflection of in vitro culture conditions (31, 32) . It has recently been proposed that the B cell activation induced by HIV-l infection is primarily directed against the virus itself (30, 32) . For example, limiting dilution analysis of PBL from AIDS patients cultured in vitro showed that 20-100% ofthese B cells produced anti-HIV antibodies (30, 33) .
The humoral immune response mounted by retrovirus-infected individuals may be important in regulating HIV replication/spread in vivo (34) (35) (36) , preventing superinfection by other pathogens, and/or mediating autoimmune damage to host tissues (37) (38) (39) (40) (41) . It is therefore important to determine: (a) the processes involved in regulating B cell activation in HIV-1-infected patients, and (b) whether changes in these processes are associated with disease progression. In addition, abnormal B cell activation is a feature of other infectious diseases (e.g., EBV, cytomegalovirus, and parasitic infections [42] [43] [44] [45] ) such that studies of HIV-1 might yield insights relevant to other diseases as well.
To examine the nature of the B cell activation present in HIV+ individuals, investigators have monitored changes in the concentration of serum antibodies and the activation state of lymphocytes cultured in vitro (6, 29, 30, 33, 46, 47) . While both of these approaches have value, it is now possible to directly monitor the number and antigenic specificity of B cells activated as a consequence of HIV infection. This can be accomplished by using an ELISA spot assay which is sensitive enough to detect the Ig produced by single freshly isolated in vivo activated peripheral blood lymphocytes (PBL; 48-51).
We used the ELISA spot technique to study large numbers of HIV-infected patients with Center for Disease Control (CDC) class II, III, and IV disease. Results indicate that HIV infection induced both virus-specific and polyclonal B cell activation. These two types of B cell activation appeared to be regulated independently, in that (a) HIV-specific responses declined as a function of disease severity while polyclonal responses increased, and (b) only polyclonal responses correlated significantly with CD4 cell number and CD4/CD8 ratio.
Methods
Subjects. A total of 86 HIV-positive patients (23 with CDC class II disease, 55 with class III, and 8 with class IV disease) were studied. (50, 52) .
Peripheral blood mononuclear cells were separated by density gradient centrifugation over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ). White blood cells recovered from the interface were washed six times in medium consisting of RPMI 1640 supplemented with 2.5% FCS. These cells were resuspended at a concentration of 10 X 106/ml. Serial dilutions of freshly isolated PBL, starting with 106 cells/well, were incubated on Ag-coated plates for 9-10 h at 37°C in a 5% CO2 in air incubator. The cells were then washed away with PBS/ 0.05% Tween 20 and the plates overlaid with phosphatase-conjugated antibodies to human IgG, IgM, and IgA (Boerhinger Mannheim Corp.). The antibodies produced by individual B cells that bound to antigen on the plate were visualized by addition ofa 5-bromo-3-chloro-4-indolyl phosphatase solution (Sigma Chemical Co., St. Louis, MO) in a low melt agarose kept at 56°C. Phosphatase acts on this substrate to produce a blue spot that cannot diffuse through the agarose once it solidifies at room temperature (48) . That dilution of cells producing -20-30 spots/well was used to calculate the total number ofantibodysecreting cells (ASC) for each antigen per 106 PBL.
The presence of BSA in the FCS used to conduct these assays completely inhibited the binding of BSA-specific antibodies to BSAblocked plates, giving the assays zero background. The sensitivity and specificity ofthis assay has been documented in antigen inhibition tests and in studies involving antigen-specific hybridoma cell lines (48) (49) (50) .
Statistical analysis. Correlation coefficients were determined using Pearson's procedure based on linear regression analysis. Statistical significance was determined used a two-tailed t test unless otherwise described.
Results
Number and specificity ofIg-secreting cells in HIV-I-infected patients. The frequency ofPBL secreting IgG, IgM, or IgA antibodies in 86 HIV+ individuals was compared with that of 51 normal donors. As seen in Table I , the number ofcells secreting Ig of each isotype was increased 1.9-3.4-fold in the patient group. An antigen-specific ELISA spot assay sensitive enough to detect one Ab-secreting cell among 106 PBL was used to determine the specificity of the antibodies produced by these cells. This assay was selected on the basis of its (a) > 20-fold higher sensitivity for spontaneously secreted Ig compared with conventional ELISAs (48) (49) (50) 53 , and data not shown), (b) freedom from artifacts induced by prolonged in vitro culture and/ or mitogenic stimulation (54) , and (c) ability to provide an accurate measure of B cell activation in vivo (48, 50, 53, 55) .
Among HIV-infected individuals, the repertoire of IgG-secreting cells was significantly skewed toward reactivity against HIV-associated antigens. Antibody from 7.1% of all IgG-producing cells specifically bound to recombinant purified HIVIIIB gpl60, a 737-fold increase over control background (P < 0.0001, Table I ). Antibody from an additional 3% ofIgG-secreting cells bound to the p24 antigen of HIV (140-fold over background, P < 0.001).
By comparison, the repertoire of IgM-and IgA-secreting cells was not skewed toward the production of gpl60 or p24 reactive antibodies. These PBL exhibited a general and proportional increase in reactivity against a diverse panel of autoantigens (DNA, myosin, actin) and conventional antigens (TNP-KLH, ovalbumin), consistent with a process of polyclonal B cell activation (Table I ). The number of cells secreting IgG antibodies against members ofthis antigen panel was increased 9-25-fold compared with controls (mean increase, 17.9-fold). This indicated either that cross-reactive B cells were being poly- Fig. 2) . Conversely, the degree ofpolyclonal B cell activation was significantly increased among patients with CDC class IV disease (P < 0.005).
Another interesting correlation was noted between CD4 count, CD4/CD8 ratio, and the degree of polyclonal activation. As seen in Table III , the proportion of cells secreting IgG antibodies against non-HIV antigens showed a significant inverse correlation with these parameters, unlike those reactive with HIV. In addition, the total number of IgG-and IgA-producing cells, and serum IgM and IgA concentration, showed significant inverse correlations with CD4 count and/or CD4/CD8 ratio (Table IV) This work established the number oflymphocytes secreting anti-gp 160 antibodies in different patient populations. We found that 2-17% (mean 7.1%) of IgG-producing cells in HIVinfected individuals reacted with recombinant purified gp 160, while 1-9% reacted with p24 (Table I ). These frequencies are consistent both with the number of anti-HIV-secreting cells induced in mice immunized and boosted with these antigens (56) and with the frequency of antigen-specific B cells found in other diseases involving chronic immunostimulation (51). (Fig. 2) . This finding is consistent with evidence from other investigators showing that disease progression is associated with a decrease in Ab titer against HIV proteins (57) (58) (59) (60) and suggests that an active humoral response against HIV may delay disease progression (or alternatively, that the ability to maintain such a response degrades as immune status declines). A possible confounding influence on these studies was the more frequent use of zidovudine by patients with advanced disease. To control for this variable, all patients receiving zidovudine therapy were analyzed independently. Again, those with the most advanced disease expressed the lowest numbers ofanti-gp 160-and anti-p24-secreting B cells (Fig. 2, legend) [23] [24] [25] [26] ), bystander stimulation due to lymphokines released by HIV-specific T cells (63) , and/or abnormalities in immune regulation resulting from a loss ofT cell function. In the case of IgG-secreting cells, there was an unexpected 9-25-fold increase in the number of non-HIV reactive lymphocytes despite an increase of only 3.4-fold in the total number of IgG-producing cells (Table I) . While indicative of polyclonal activation, this result further suggests that a subpopulation of highly crossreactive B cells might be specifically stimulated in HIV+ individuals. This possibility is currently under investigation.
There was a significant inverse correlation between the number of IgG-secreting B cells among patients and their CD4 cell count, suggesting that these two processes may be causally linked (Table IV) . Indeed, an association between polyclonal B cell activation and defective T4 function has been reported in other disease states, such as experimentally induced graft-versus-host disease, murine lupus, and murine AIDS (41, (64) (65) (66) (67) (68) .
The level ofB cell activation found in HIV-infected individuals is comparable to that detected in patients with autoimmune diseases such as systemic lupus erythematosus (69) . This polyclonal activation is associated both with the production of pathogenic autoantibodies (such as IgG anti-DNA) and the suppression ofimmune responses to foreign antigens. It is possible that pathogenic organisms (e.g., HIV, EBV, cytomegalovirus) "intentionally" induce polyclonal responses in an effort to suppress the host's capacity to mount a specific response against the pathogen. In this context, it is interesting to note the inverse correlation between polyclonal activation and HIVspecific responses manifest by patients with CDC class II and III versus IV disease (Fig. 2) . Ongoing research may elucidate the mechanism(s) by which HIV and other pathogens abnormally activate host B cells and determine the effect ofthis process on disease progression.
